Does Fosamax Cause Osteonecrosis of the Jaw?

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Science to Occupational Exposure Concerns

The legacy of general health and science information has long served as a foundation for public understanding of medical risks and therapeutic benefits. Within this broad domain, discussions of pharmaceutical safety have historically emphasized the balance between efficacy and adverse effects, often framed in terms of population-level outcomes and clinical guidelines. This heritage provides a structured approach to evaluating how medications interact with biological systems, yet it typically remains anchored in generalized patient populations and standard prescribing contexts. Transitioning from this broad perspective, a more focused concern emerges when considering specific exposure scenarios. In mass production environments, the routine handling of pharmaceutical compounds introduces distinct occupational variables that differ from patient consumption patterns. Workers may encounter active ingredients through inhalation, dermal contact, or accidental ingestion during manufacturing processes, leading to chronic low-level or intermittent high-level exposures. This shift in context—from therapeutic use to occupational contact—necessitates a reexamination of risk profiles. For instance, bisphosphonate compounds like Fosamax, when studied in clinical settings, are evaluated for their intended effects on bone density. However, in occupational settings, the potential for unintended exposure raises questions about cumulative impact on oral health, particularly regarding jaw integrity. The bridge from general health literacy to occupational exposure concern thus lies in recognizing that manufacturing workflows can create unique pathways for chemical interaction, warranting separate scrutiny beyond traditional patient-focused warnings.

Bridging to Fosamax and Jaw Health

Fosamax (alendronate sodium) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The drug works by inhibiting bone resorption, thereby increasing bone mass and reducing fracture risk. However, a known adverse effect associated with bisphosphonate use, including Fosamax, is osteonecrosis of the jaw (ONJ). Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The clinical presentation of ONJ often involves pain, swelling, infection, and exposed bone in the jaw, which may persist for weeks to months. Diagnosis is typically based on clinical examination and imaging, with a focus on ruling out other causes such as malignancy or radiation-induced osteonecrosis.

Mechanistic Evidence and Risk Factors

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated, but current evidence suggests that bisphosphonates, including Fosamax, may impair bone remodeling and vascular supply in the jawbone. Bisphosphonates accumulate in bone and inhibit osteoclast activity, which can lead to reduced bone turnover and compromised healing after dental procedures or trauma. This is supported by multiscale characterization of jawbone, which provides comprehensive information to better understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). The jawbone's unique anatomy and high turnover rate may make it particularly susceptible to these effects. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates. For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ. The time to onset of symptoms after starting Fosamax can vary from one day to several months (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients experience relief of symptoms after discontinuing the drug, but a subset may have recurrence of symptoms when rechallenged with the same drug or another bisphosphonate. In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups, suggesting that while ONJ is a known adverse effect, its incidence in the general osteoporosis population may be low.

Adequacy of Warnings and Causation Considerations

Regarding the adequacy of warnings, the prescribing information for Fosamax includes a specific section on osteonecrosis of the jaw under 'Warnings and Precautions' (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This section advises clinicians to consider discontinuation of bisphosphonate treatment for patients requiring invasive dental procedures to reduce the risk of ONJ. The label also notes that ONJ has been reported in patients taking bisphosphonates, including Fosamax, and outlines known risk factors. However, the label does not provide specific guidance on the optimal duration of use for osteoporosis treatment, noting that the optimal duration has not been determined and that for low-risk patients, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For affected patients, causation considerations involve evaluating the temporal relationship between Fosamax exposure and the development of ONJ, as well as the presence of other risk factors. The timeline between exposure and documented harm can range from days to months after starting the drug, and symptoms may persist or recur after discontinuation. Patients with ONJ should be managed in consultation with a dental professional, and discontinuation of Fosamax may be considered, especially if severe symptoms develop. In summary, Fosamax is associated with osteonecrosis of the jaw, a condition that can occur spontaneously or after dental procedures. The risk is influenced by duration of use and other factors, and warnings are included in the prescribing information. Patients and healthcare providers should weigh the benefits of Fosamax for osteoporosis prevention against the potential risk of ONJ, particularly in those with additional risk factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is osteonecrosis of the jaw (ONJ)?

Osteonecrosis of the jaw is a condition characterized by exposed, non-healing bone in the maxillofacial region, often associated with pain, swelling, and infection. It can occur spontaneously or after dental procedures, and is a known adverse effect of bisphosphonate medications like Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

How does Fosamax cause osteonecrosis of the jaw?

Fosamax inhibits bone resorption by suppressing osteoclast activity, which can impair bone remodeling and vascular supply in the jawbone. This may lead to compromised healing after dental trauma or infection, contributing to ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease or anemia (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.